Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | F11 | P03951 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6464475 | 0.89 | MMP2 (0.46) | MMP2MMP3MMP7F2F10 | |
| SCHEMBL7133729 | 0.81 | SMN1; SMN2 (0.42) | MMP3CTSKCTSLCTSB | |
| SCHEMBL7045498 | 0.80 | PRSS8 (0.49) | CYP3A4CES1CTSKCTSLCTSB | |
| SCHEMBL6465941 | 0.80 | CTSL (0.40) | CTSLCTSB | |
| SCHEMBL7043357 | 0.78 | PLA2G4A (0.45) | MMP2MMP3MMP7F2F10 | |
| SCHEMBL6462329 | 0.77 | PLA2G4A (0.44) | MMP2MMP3MMP7F2F10 | |
| SCHEMBL7130607 | 0.76 | SMN1; SMN2 (0.42) | MMP3CTSKCTSLCTSB | |
| SCHEMBL7046962 | 0.74 | PRSS8 (0.49) | CYP3A4CES1CTSKCTSLCTSB | |
| SCHEMBL6467453 | 0.74 | MMP2 (0.55) | MMP2MMP3MMP7F2F10 | |
| SCHEMBL7137505 | 0.74 | SMN1; SMN2 (0.41) | MMP3CTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | MMP2 91/4885MMP3 72/4885MMP7 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.